Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) EBT Margin (2018 - 2025)

Cue Biopharma (CUE) has disclosed EBT Margin for 8 consecutive years, with 244.28% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 125419.0% to 244.28% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 31.5% through Dec 2025, up 4299.0% year-over-year, with the annual reading at 17.02% for FY2025, 5748.0% up from the prior year.
  • EBT Margin hit 244.28% in Q4 2025 for Cue Biopharma, up from 343.09% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1498.48% in Q4 2024 to a low of 50800.0% in Q2 2022.
  • Historically, EBT Margin has averaged 4582.56% across 5 years, with a median of 623.79% in 2021.
  • Biggest five-year swings in EBT Margin: plummeted -5042472bps in 2022 and later skyrocketed 4986274bps in 2023.
  • Year by year, EBT Margin stood at 95.58% in 2021, then crashed by -9763bps to 9426.49% in 2022, then soared by 92bps to 709.88% in 2023, then skyrocketed by 311bps to 1498.48% in 2024, then tumbled by -84bps to 244.28% in 2025.
  • Business Quant data shows EBT Margin for CUE at 244.28% in Q4 2025, 343.09% in Q3 2025, and 285.61% in Q2 2025.